Purpose of this Study
We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.
Who Can Participate?
Eligibility
Adults ages 18 and older who:
- Are diagnosed with stage III or IV endometrial, prostate, hepatobiliary, pancreatic, and gastrointestinal cancers with certain tumor mutations
- Do not have prostate tumors with small cell component
- Are not pregnant or breastfeeding
- Are diagnosed with stage III or IV endometrial, prostate, hepatobiliary, pancreatic, and gastrointestinal cancers with certain tumor mutations
- Do not have prostate tumors with small cell component
- Are not pregnant or breastfeeding
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will:
- Go through a screening period to see if you're eligible for the study
- Start participating before, during, or after treatment with standard of care immunotherapy for your cancer
If you're eligible to join, you will:
- Be monitored until you complete your immunotherapy treatment and the final blood and/or tissue samples are collected
- Provide the following depending on when you enroll in the study (before, during, or after immunotherapy):
-- Blood samples
-- Stool samples
-- Tumor tissue samples
- Go through a screening period to see if you're eligible for the study
- Start participating before, during, or after treatment with standard of care immunotherapy for your cancer
If you're eligible to join, you will:
- Be monitored until you complete your immunotherapy treatment and the final blood and/or tissue samples are collected
- Provide the following depending on when you enroll in the study (before, during, or after immunotherapy):
-- Blood samples
-- Stool samples
-- Tumor tissue samples
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS (PAIR-MSI)
Principal Investigator
Nicholas
DeVito
Protocol Number
PRO00105726
NCT ID
NA
Enrollment Status
OPEN TO ACCRUAL